MedTrace Logo

Remdesivir Efficacy In Management Of COVID-19 Patients

NCT04853901 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2021-04-22

No results posted yet for this study

Summary

The study is open label randomized interventional phase 3 clinical trial. Patients with confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain Shams University and Assiut University ) assigned hospitals for isolation.

Conditions

  • Covid19

Interventions

DRUG

Remdesivir

Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days

DRUG

Standard of care_1

Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days

DRUG

Standard of care_2

Methylprednisolone 1-2mg/kg for 5-7 days

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Hany E Dabbous, M.D · Faculty of Medicine Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2021-01-01
Completion
2021-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853901 on ClinicalTrials.gov